iSBTc 23rd Annual Meeting

Annual Meeting Main Page   |   Program Purpose   |   Faculty   |   Schedule   |   Support Opportunities
Registration   |   Hotel   |   Abstracts   |   Award Information   |   Dates to Remember/Deadlines
CME Information   |   Supporters

October 31 - November 2, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA

The iSBTc Annual Meeting facilitates exchange of the most cutting edge preclinical and clinical data on the use of biological therapies in cancer between basic scientists and clinicians from academic, regulatory and industrial venues. This meeting will provide education on the latest advances and allow investigators to share and build on their data, ultimately leading to better patient outcomes in cancer.

Topics to be Addressed

  • Adoptive Transfer
  • Cancer Stem Cells and the Host Response
  • Co-Stimulation / Immunoregulation *
  • Dendritic Cells *
  • Endpoints, Response Criteria for Clinical Trial Design
  • Enhancing Cancer Vaccines
  • Infectious Agent Vectors *


  • Innate Immunity to Tumors
  • New Agents *
  • TH-17, Cytokines and T Cell Subsets
  • Trafficking and in vivo Imaging *
  • Tumor Escape / Tumor Microenvironment
  • Tumor Targeting Monoclonal Antibodies

(* indicates a poster only category)

Intended Audience
Basic and clinical investigators involved in cancer research comprising members of academic, pharmaceutical and regulatory agencies including basic scientists, clinicians, graduate students and post-doctoral fellows, as well as allied health professionals.

Program Objectives

  • Promote scientific exchange of most recent advances and data in the biological treatment of cancer, as well as advances in basic cancer biology with relevance for anti-tumor immunity
  • Promote the generation of new ideas incorporating these advances and explore their potential for impact on treatment outcomes
  • Discuss the latest clinical developments regarding application of biologic approaches and establish dialogue between academia, government, and industry regarding implications as well as future directions
  • Educate and provide perspective to the audience on the broad range of scientific developments in cancer and biological approaches to therapy
  • Discuss current approaches to immunological monitoring
  • Discuss current regulatory guidelines and how they impact clinical trials as well as resource availability

Expected Outcomes
Upon completion of this meeting, attendees will have:

  • Learner about the most recent advances in cancer biology, how they intersect with the immune system, and how these considerations are relevant for the biologic therapy of cancer . These include but are not limited to: cancer stem cells, inflammation and cancer, cancer dormancy, and angiogenesis.
  • Experienced the latest information about clinical/translational work in cancer immunotherapy. Therapeutic approaches to be discussed will include: cancer vaccines, adoptive T cell transfer, monoclonal antibodies, gene therapy, and use of cytotoxic or molecular targeting agents in combination with immune therapy.
  • Established or solidified collaborations among the various members of academia, industry, and clinical practices to initiate clinical evaluation of these advances in more efficient trials.
  • Learned about options available in trial design including immune monitoring techniques and compliance with regulatory guidelines.
  • Learned about resources available through government agencies (funds, data-bases, tissue banks, etc.) that can facilitate translational research.

Organizers
Thomas A. Davis, MD
Celldex Therapeutics, Inc.

Thomas F. Gajewski, MD, PhD
University of Chicago 		William J. Murphy, PhD
University of Nevada School of Medicine

Hideaki Tahara, MD, PhD
University of Tokyo